Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Actinium Pharmaceuticals Inc (ATNM)

Actinium Pharmaceuticals Inc (ATNM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 46,482
  • Shares Outstanding, K 31,196
  • Annual Sales, $ 0 K
  • Annual Income, $ -38,240 K
  • EBIT $ -49 M
  • EBITDA $ -48 M
  • 60-Month Beta -0.32
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.91

Options Overview Details

View History
  • Implied Volatility 163.82% ( -54.47%)
  • Historical Volatility 87.75%
  • IV Percentile 28%
  • IV Rank 9.25%
  • IV High 1,085.36% on 03/11/25
  • IV Low 69.85% on 09/25/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 72
  • Volume Avg (30-Day) 37
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 2,436
  • Open Int (30-Day) 2,273

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.33
  • Number of Estimates 2
  • High Estimate -0.32
  • Low Estimate -0.33
  • Prior Year -0.38
  • Growth Rate Est. (year over year) +13.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3500 +17.78%
on 07/02/25
1.7100 -7.02%
on 06/25/25
+0.0600 (+3.92%)
since 06/16/25
3-Month
1.1650 +36.48%
on 04/21/25
1.9454 -18.27%
on 06/10/25
+0.3400 (+27.20%)
since 04/16/25
52-Week
1.0292 +54.49%
on 03/04/25
8.6400 -81.60%
on 07/23/24
-6.1700 (-79.51%)
since 07/16/24

Most Recent Stories

More News
Investors Bet on Biotech as Public Cancer Research Hits a Wall

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – As cancer rates continue to climb worldwide, the race to develop better, faster, and more affordable treatments...

ONCY : 1.2500 (+10.62%)
AGEN : 6.36 (+2.25%)
OLMA : 4.56 (-0.65%)
ICCM : 1.0300 (+1.98%)
ONC.TO : 1.70 (+11.11%)
ATNM : 1.5900 (+6.71%)
With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz

/CNW/ -- Equity Insider News Commentary – Routine medical appointments or cancer screenings—critical for catching the disease in earlier, more treatable...

ONCY : 1.2500 (+10.62%)
ONC : 279.16 (+3.51%)
CVM : 3.85 (+9.07%)
ONC.TO : 1.70 (+11.11%)
ATNM : 1.5900 (+6.71%)
OSTX : 1.6800 (+6.33%)
Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements

EQNX::TICKER_START (NYSE:ATNM),(NYSE:BMY),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AZN) EQNX::TICKER_END

AZN : 70.08 (-0.34%)
LLY : 789.80 (+2.34%)
NVS : 118.37 (-1.09%)
ATNM : 1.5900 (+6.71%)
BMY : 47.17 (+1.59%)
Regencell, GlucoTrack, TC Biopharm, AbbVie, Actinium: 5 Health Care Stocks That Lit Up Retail Discussions Last Week

Investors reacted to insider buying, clinical trial updates, and strategic business shifts that happened in the week ended March 21, 2025.

GCTK : 5.34 (-1.93%)
TCBP : 0.5000 (-67.53%)
ABBV : 190.58 (+2.25%)
ATNM : 1.5900 (+6.71%)
RGC : 15.29 (+11.61%)
Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A’s Backbone Therapy Strategy

New York, NY – March 20, 2025 – Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that is has...

ATNM : 1.5900 (+6.71%)
Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates

Amarin Corporation plc AMRN reported an adjusted loss of 5 cents per share for the third quarter of 2024, which was in line with the Zacks Consensus Estimate. The company had reported breakeven earnings...

FOLD : 6.07 (+2.71%)
AMRN : 15.85 (+0.44%)
ARDX : 4.60 (+2.22%)
ATNM : 1.5900 (+6.71%)
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View

Corcept Therapeutics Incorporated CORT reported third-quarter 2024 earnings of 41 cents per share, which significantly beat the Zacks Consensus Estimate of 27 cents. The company had reported earnings of...

FOLD : 6.07 (+2.71%)
CORT : 72.85 (+2.02%)
ARDX : 4.60 (+2.22%)
ATNM : 1.5900 (+6.71%)
Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 18, 2024) - Investorideas.com, a go-to investing platform covering biotech and medical technology stocks releases the second of a...

ATNM : 1.5900 (+6.71%)
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase

EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END

LGVN : 1.4600 (-0.68%)
SLS : 1.9200 (+1.05%)
ATNM : 1.5900 (+6.71%)
BPTH : 0.1570 (-3.62%)
BMY : 47.17 (+1.59%)
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase

LGVN : 1.4600 (-0.68%)
SLS : 1.9200 (+1.05%)
ATNM : 1.5900 (+6.71%)
BPTH : 0.1570 (-3.62%)
BMY : 47.17 (+1.59%)

Business Summary

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application for their ARCs is targeted conditioning, which is intended...

See More

Key Turning Points

3rd Resistance Point 1.7413
2nd Resistance Point 1.6751
1st Resistance Point 1.6325
Last Price 1.5900
1st Support Level 1.5237
2nd Support Level 1.4575
3rd Support Level 1.4149

See More

52-Week High 8.6400
Fibonacci 61.8% 5.7327
Fibonacci 50% 4.8346
Fibonacci 38.2% 3.9365
Last Price 1.5900
52-Week Low 1.0292

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar